Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.

被引：2
|
作者：
Gajria, D. [1 ]
King, T. A. [1 ]
Pannu, H. [1 ]
Sakr, R. [1 ]
Seidman, A. D. [1 ]
Syldor, A. [1 ]
Patil, S. [1 ]
Maybody, M. [1 ]
Norton, L. [1 ]
Rosen, N. [1 ]
Hudis, C. [1 ]
Chandarlapaty, S. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.574
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
574
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer.
    Burris, H. A.
    Krop, I. E.
    Modi, S.
    Rodon, J.
    Lutzker, S. G.
    Holden, S. N.
    Bhattacharya, S.
    Sliwkowski, M. X.
    Beeram, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S104 - S104
  • [22] Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
    Floros, Konstantinos, V
    Jacob, Sheeba
    Kurupi, Richard
    Fairchild, Carter K.
    Hu, Bin
    Puchalapalli, Madhavi
    Koblinski, Jennifer E.
    Dozmorov, Mikhail G.
    Boikos, Sosipatros A.
    Scaltriti, Maurizio
    Faber, Anthony C.
    CELL DEATH & DISEASE, 2021, 12 (02)
  • [23] Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
    Konstantinos V. Floros
    Sheeba Jacob
    Richard Kurupi
    Carter K. Fairchild
    Bin Hu
    Madhavi Puchalapalli
    Jennifer E. Koblinski
    Mikhail G. Dozmorov
    Sosipatros A. Boikos
    Maurizio Scaltriti
    Anthony C. Faber
    Cell Death & Disease, 12
  • [24] Phase 1 study of triweekly nab-paclitaxel combined with S-1 in patients with HER2 negative metastatic breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sakaguchi, Kouichi
    Hujita, Yoshihumi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Prognostic role of plasma HER2 gene copy number in patients with HER2 positive metastatic breast cancer.
    Ran, Ran
    Huang, Wenfa
    Lin, Shao
    Niu, Yunyun
    Rugo, Hope S.
    Kong, Weiyao
    Bo, Shiping
    Lu, Sijia
    Li, Huiping
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in Chinese patients with HER2+ metastatic breast cancer.
    Xu, Binghe
    Ma, Fei
    Chen, Shanshan
    Li, Qiao
    Yang, Fan
    Zhang, Yifan
    Chen, Xiaoyan
    Zhong, Dafang
    Zhang, Ge
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.
    Kong, SY
    Kwon, Y
    Lee, DH
    Lee, JS
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
  • [28] Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
    Xue, Cong
    Yao, Herui
    Lin, Ying
    An, Xin
    Chen, Meiting
    Dong, Yugang
    Li, Su
    Shi, Yanxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Early results of combined Her-2/neu (HER2) immunotherapy using a HER2 peptide vaccine with concurrent trastuzumab for metastatic breast cancer.
    Webster, D.
    Waisman, J.
    MacLeod, B.
    dela Rosa, C.
    Higgins, D.
    Fintak, P.
    Childs, J.
    Slota, M.
    Salazar, L.
    Disis, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S79 - S80
  • [30] Hyperactivation of mTORC1 drives acquired resistance to the pan HER tyrosine kinase inhibitor neratinib in HER2 mutant cancers
    Sudhan, Dhivya R.
    Hanker, Ariella B.
    Guerrero-Zotano, Angel
    Formisano, Luigi
    Guo, Yan
    Liu, Qi
    Avogadri-Connors, Francesca
    Cutler, Richard E.
    Lalani, Alshad S.
    Bryce, Richard
    Auerbach, Alan
    Arteaga, Carlos L.
    CANCER RESEARCH, 2018, 78 (13)
12345